LGBT Cancer Project

Liver Cancer Clinical Trials

A listing of Liver Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

NEW

Research Center
Additional Locations Alabama

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Research Site
Birmingham Alabama

A Phase 3 Study (PHOCUS) to determine whether the oncolytic virus immunotherapy called Pexa-Vec (JX-594) can slow the progression of advanced liver cancer (hepatocellular carcinoma or HCC).

Alaska

NEW

Research Center
Additional Locations Alaska

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Arizona

NEW

Research Center
Additional Locations Arizona

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Research Center
Phoenix Arizona

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
Phoenix Arizona

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Site
Scottsdale Arizona

A Phase 3 Study (PHOCUS) to determine whether the oncolytic virus immunotherapy called Pexa-Vec (JX-594) can slow the progression of advanced liver cancer (hepatocellular carcinoma or HCC).

Contact Incyte Corporation Call Center at 1.855.463.3463
Tucson Arizona

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
Tucson Arizona

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
Tucson Arizona

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

California

NEW

Research Center
Additional Locations California

A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)

NEW

Research Center
Additional Locations California

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Research Site
Irvine California

A Phase 3 Study (PHOCUS) to determine whether the oncolytic virus immunotherapy called Pexa-Vec (JX-594) can slow the progression of advanced liver cancer (hepatocellular carcinoma or HCC).

Research Center
Orange California

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
Orange California

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
San Francisco California

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Contact Incyte Corporation Call Center at 1.855.463.3463
San Francisco California

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
San Francisco California

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Site
Stanford California

A Phase 3 Study (PHOCUS) to determine whether the oncolytic virus immunotherapy called Pexa-Vec (JX-594) can slow the progression of advanced liver cancer (hepatocellular carcinoma or HCC).

Daly City California 94115

A Phase 3 clinical study for patients with Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

La Jolla California 92093

A Phase 1 clinical study for patients with Hepatocellular Carcinoma or Cirrhosis

Los Agneles California 90033

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Los Angeles California 90033

A clinical trial seeking patients for a research study for the treatment of Hepatocellular Carcinoma

Los Angeles California 90033

A clinical trial to evaluate treatments using INT230-6, anti-PD-1 and anti-PD-1 antibody for patients

Los Angeles California 90095-6984

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Los Angeles California 90033

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Los Angeles California 90024

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Los Angeles California 90025

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Los Angeles California 90095

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Los Angeles California 90095

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Los Angeles California 90033

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Los Angeles California 90024

A Phase 3 clinical study for patients with Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

Newport Beach California 92663

A clinical trial to evaluate treatments using INT230-6, anti-PD-1 and anti-PD-1 antibody for patients

Newport Beach California 92663

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Rialto California 92377

A clinical trial to evaluate treatments using BLU-554 for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma

San Diego California 92123

A clinical trial seeking patients for a research study for the treatment of Hepatocellular Carcinoma

San Francisco California 94115

A clinical trial seeking patients for a research study for the treatment of Hepatocellular Carcinoma

Santa Monica California 90403

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Santa Monica California 90404

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Santa Monica California 90404

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors

Colorado

NEW

Research Center
Additional Locations Colorado

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Contact Incyte Corporation Call Center at 1.855.463.3463
Aurora Colorado

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
Aurora Colorado

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
Aurora Colorado

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
Denver Colorado

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
Denver Colorado

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Connecticut

NEW

Research Center
Additional Locations Connecticut

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC

Research Center
New Haven Connecticut

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Research Center
New Haven Connecticut

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Farmington Connecticut 06030-2205

A Phase 1 clinical study for patients with Neoplasms, Advanced Solid Tumors